- Home
- CDLR vs VRDN Comparison
CDLR vs VRDN Comparison
Compare CDLR & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CDLR | VRDN |
|---|---|---|
| Founded | 2008 | 2006 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.1B |
| IPO Year | 2025 | 2014 |
Fundamental Metrics
Financial Performance| Metric | CDLR | VRDN |
|---|---|---|
| Price | $6.71 | $30.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 17 |
| Target Price | N/A | ★ $42.19 |
| AVG Volume (30 Days) | 144.5K | ★ 2.8M |
| Earning Date | 11-23-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,706,000.00 |
| Revenue This Year | $57.98 | $6.01 |
| Revenue Next Year | $37.55 | $316.34 |
| P/E Ratio | $7.39 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.44 | $13.18 |
| 52 Week High | $32.81 | $34.29 |
Technical Indicators
Market Signals| Indicator | CDLR | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 21.28 | 78.19 |
| Support Level | $6.44 | $17.84 |
| Resistance Level | $25.23 | $30.79 |
| Average True Range (ATR) | 1.56 | 1.51 |
| MACD | -1.85 | 0.51 |
| Stochastic Oscillator | 0.87 | 89.10 |
Price Performance
Historical ComparisonAbout CDLR Cadeler AS
Cadeler AS is an offshore wind installation vessel contractor. It currently operates various offshore jack-up wind installation vessels, with new builds on order. The Group operates within the market for the transportation and installation of offshore wind turbine generators (WTGs) and their foundations. In addition to wind farm installation, its vessels can perform maintenance, decommissioning, and other general construction tasks within the offshore industry. Cadler's customer base consists of offshore wind farm developers, original equipment manufacturers, and various offshore contractors. Geographically, the Group generates maximum revenue from the United States and the rest from the United Kingdom, Taiwan, Germany, Denmark, Poland, and other regions.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.